67.4 ± 13.8), positive lymph node metastasis (84.2 ± 18.5 vs. 70.6 ± 14.8), positive ER (81.3 ± 19.7 vs. 70.6 ± 14.8), positive PR (79.5 ± 19.1 vs. 72.5 ± 14.7), and positive HER2 (80.7 ± 19.0 vs. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.